{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:26:18Z","timestamp":1771867578936,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of of China","award":["No. 82270175"],"award-info":[{"award-number":["No. 82270175"]}]},{"name":"Natural Science Foundation of Fujian Province of China","award":["2021J02040"],"award-info":[{"award-number":["2021J02040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic lymphocytic leukemia (CLL) is one of the most frequent occurring types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. At present, the molecular mechanism driving the pathogenesis and progression of CLL is not fully understood. The protein Synaptotagmin 7 (SYT7) encoded by the SYT7 gene has been found to be closely related to the development of various solid tumors, but its role in CLL is unclear. In this study, we investigated the function and molecular mechanism of SYT7 in CLL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression level of SYT7 in CLL was determined by immunohistochemical staining and qPCR. The role of SYT7 in promoting CLL development was verified by in vivo and in vitro experiments. The molecular mechanism of SYT7 in CLL was elucidated by methods such as GeneChip analysis and Co-immunoprecipitation assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Malignant behaviors such as proliferation, migration, and anti-apoptosis of CLL cells were significantly inhibited after SYT7 gene knockdown. In contrast, SYT7 overexpression promoted CLL development in vitro. Consistently, the knockdown of SYT7 also inhibited xenograft tumor growth of CLL cells. Mechanistically, SYT7 promoted CLL development by inhibiting SYVN1-mediated KNTC1 ubiquitination. The KNTC1 knockdown also attenuated the effects of SYT7 overexpression on development of CLL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SYT7 regulates the progression of CLL through SYVN1-mediated KNTC1 ubiquitination, which has potential value for molecular targeted therapy of CLL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40364-023-00506-4","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T04:02:48Z","timestamp":1686024168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["SYT7 regulates the progression of chronic lymphocytic leukemia through interacting and regulating KNTC1"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4326-8552","authenticated-orcid":false,"given":"Wenjie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zezhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-3990","authenticated-orcid":false,"given":"Zhenshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"issue":"1","key":"506_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","volume":"14","author":"K Patel","year":"2021","unstructured":"Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021;14(1):69.","journal-title":"J Hematol Oncol"},{"key":"506_CR2","doi-asserted-by":"crossref","unstructured":"Mavridou D, Psatha K, Aivaliotis M. Proteomics and drug Repurposing in CLL towards Precision Medicine. Cancers (Basel). 2021;13(14):3391.","DOI":"10.3390\/cancers13143391"},{"issue":"9","key":"506_CR3","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","volume":"106","author":"R Svanberg","year":"2021","unstructured":"Svanberg R, Janum S, Patten PEM, Ramsay AG, Niemann CU. Targeting the tumor microenvironment in chronic lymphocytic leukemia. Haematologica. 2021;106(9):2312\u201324.","journal-title":"Haematologica"},{"issue":"2","key":"506_CR4","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1097\/HS9.0000000000000175","volume":"3","author":"DY Yosifov","year":"2019","unstructured":"Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From Biology to Therapy: the CLL Success Story. Hemasphere. 2019;3(2):e175.","journal-title":"Hemasphere"},{"issue":"1","key":"506_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10020-018-0001-1","volume":"24","author":"G Ferrer","year":"2018","unstructured":"Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Mol Med. 2018;24(1):9.","journal-title":"Mol Med"},{"key":"506_CR6","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.","journal-title":"Nat Rev Dis Primers"},{"key":"506_CR7","doi-asserted-by":"crossref","unstructured":"Putowski M, Giannopoulos K. Perspectives on Precision Medicine in Chronic lymphocytic leukemia: targeting recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3. J Clin Med. 2021;10(16):3735.","DOI":"10.3390\/jcm10163735"},{"issue":"3","key":"506_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24282","volume":"91","author":"KR Rai","year":"2016","unstructured":"Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol. 2016;91(3):330\u201340.","journal-title":"Am J Hematol"},{"issue":"9","key":"506_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer. 2019;125(9):1432\u201340.","journal-title":"Cancer"},{"key":"506_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","volume":"9","author":"S Zhang","year":"2014","unstructured":"Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014;9:103\u201318.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"506_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/emboj\/21.3.270","volume":"21","author":"S Sugita","year":"2002","unstructured":"Sugita S, Shin OH, Han W, Lao Y, S\u00fcdhof TC. Synaptotagmins form a hierarchy of exocytotic ca(2+) sensors with distinct ca(2+) affinities. EMBO J. 2002;21(3):270\u201380.","journal-title":"EMBO J"},{"issue":"7584","key":"506_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature16507","volume":"529","author":"SL Jackman","year":"2016","unstructured":"Jackman SL, Turecek J, Belinsky JE, Regehr WG. The calcium sensor synaptotagmin 7 is required for synaptic facilitation. Nature. 2016;529(7584):88\u201391.","journal-title":"Nature"},{"issue":"44","key":"506_CR13","doi-asserted-by":"publisher","first-page":"19032","DOI":"10.1073\/pnas.1014070107","volume":"107","author":"M Segovia","year":"2010","unstructured":"Segovia M, Al\u00e9s E, Montes MA, Bonifas I, Jemal I, Lindau M, et al. Push-and-pull regulation of the fusion pore by synaptotagmin-7. Proc Natl Acad Sci USA. 2010;107(44):19032\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"506_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.neuron.2017.05.011","volume":"94","author":"C Chen","year":"2017","unstructured":"Chen C, Jonas P, Synaptotagmins. That\u2019s why so many. Neuron. 2017;94(4):694\u20136.","journal-title":"Neuron"},{"issue":"7681","key":"506_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nature24474","volume":"551","author":"J Turecek","year":"2017","unstructured":"Turecek J, Jackman SL, Regehr WG. Synaptotagmin 7 confers frequency invariance onto specialized depressing synapses. Nature. 2017;551(7681):503\u20136.","journal-title":"Nature"},{"key":"506_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.conb.2020.02.006","volume":"63","author":"V Huson","year":"2020","unstructured":"Huson V, Regehr WG. Diverse roles of Synaptotagmin-7 in regulating vesicle fusion. Curr Opin Neurobiol. 2020;63:42\u201352.","journal-title":"Curr Opin Neurobiol"},{"issue":"39","key":"506_CR17","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1038\/s41388-018-0335-8","volume":"37","author":"M Kanda","year":"2018","unstructured":"Kanda M, Tanaka H, Shimizu D, Miwa T, Umeda S, Tanaka C, et al. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene. 2018;37(39):5355\u201366.","journal-title":"Oncogene"},{"key":"506_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2019.07.071","volume":"46","author":"X Liu","year":"2019","unstructured":"Liu X, Li C, Yang Y, Liu X, Li R, Zhang M, et al. Synaptotagmin 7 in twist-related protein 1-mediated epithelial - mesenchymal transition of non-small cell lung cancer. EBioMedicine. 2019;46:42\u201353.","journal-title":"EBioMedicine"},{"issue":"4","key":"506_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1530\/ERC-21-0146","volume":"29","author":"S Dong","year":"2022","unstructured":"Dong S, Pan J, Shen YB, Zhu LX, Chen L, Zhu F, et al. SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination. Endocr Relat Cancer. 2022;29(4):175\u201389.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"506_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41467-022-35778-1","volume":"14","author":"ZA Hing","year":"2023","unstructured":"Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, et al. Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter\u2019s transformation. Nat Commun. 2023;14(1):97.","journal-title":"Nat Commun"},{"issue":"1","key":"506_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12943-022-01496-x","volume":"21","author":"AM Hortal","year":"2022","unstructured":"Hortal AM, Oeste CL, Cifuentes C, Alcoceba M, Fernandez-Pisonero I, Clavain L, et al. Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. Mol Cancer. 2022;21(1):35.","journal-title":"Mol Cancer"},{"issue":"2","key":"506_CR22","first-page":"455","volume":"54","author":"XL Chen","year":"2019","unstructured":"Chen XL, Wang SF, Liang XT, Liang HX, Wang TT, Wu SQ, et al. SENP2 exerts an antitumor effect on chronic lymphocytic leukemia cells through the inhibition of the notch and NF\u03baB signaling pathways. Int J Oncol. 2019;54(2):455\u201366.","journal-title":"Int J Oncol"},{"issue":"12","key":"506_CR23","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1038\/s41375-019-0526-5","volume":"33","author":"S Wang","year":"2019","unstructured":"Wang S, Ge M, Cui J, Qiao Z, Chen X, Wu S, et al. Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia. Leukemia. 2019;33(12):2951\u20136.","journal-title":"Leukemia"},{"issue":"7","key":"506_CR24","doi-asserted-by":"publisher","first-page":"a015826","DOI":"10.1101\/cshperspect.a015826","volume":"6","author":"IM Cheeseman","year":"2014","unstructured":"Cheeseman IM. The kinetochore. Cold Spring Harb Perspect Biol. 2014;6(7):a015826.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"506_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0092-8674(03)00115-6","volume":"112","author":"DW Cleveland","year":"2003","unstructured":"Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell. 2003;112(4):407\u201321.","journal-title":"Cell"},{"key":"506_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.cellbio.18.032002.132412","volume":"18","author":"JR McIntosh","year":"2002","unstructured":"McIntosh JR, Grishchuk EL, West RR. Chromosome-microtubule interactions during mitosis. Annu Rev Cell Dev Biol. 2002;18:193\u2013219.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"16","key":"506_CR27","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1158\/0008-5472.CAN-18-3235","volume":"79","author":"DH Bach","year":"2019","unstructured":"Bach DH, Zhang W, Sood AK. Chromosomal instability in Tumor initiation and development. Cancer Res. 2019;79(16):3995\u20134002.","journal-title":"Cancer Res"},{"issue":"7","key":"506_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nrm2718","volume":"10","author":"AJ Holland","year":"2009","unstructured":"Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 2009;10(7):478\u201387.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"506_CR29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nrc1502","volume":"4","author":"N Keen","year":"2004","unstructured":"Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4(12):927\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"506_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41419-022-05140-w","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Liu R, Guo Z, Ren J, Huang J, Luo Q, et al. shRNAmediated knockdown of KNTC1 inhibits non-small-cell lung cancer through regulating PSMB8. Cell Death Dis. 2022;13(8):685.","journal-title":"Cell Death Dis"},{"key":"506_CR31","doi-asserted-by":"publisher","first-page":"110498","DOI":"10.1016\/j.cellsig.2022.110498","volume":"101","author":"H Tong","year":"2023","unstructured":"Tong H, Liu X, Peng C, Shen B, Zhu Z. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K\/Akt pathway. Cell Signal. 2023;101:110498.","journal-title":"Cell Signal"},{"issue":"4","key":"506_CR32","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.1080\/21655979.2022.2061144","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Wang Y, Liu C, Meng X, Hang Z. Kinetochore-associated protein 1 promotes the invasion and tumorigenicity of cervical cancer cells via matrix metalloproteinase-2 and matrix metalloproteinase-9. Bioengineered. 2022;13(4):9495\u2013507.","journal-title":"Bioengineered"},{"key":"506_CR33","doi-asserted-by":"publisher","unstructured":"Liu L, Chen H, Chen X, Yao C, Shen W, Jia C. KNTC1 as a putative tumor oncogene in pancreatic cancer. J Cancer Res Clin Oncol. 2022. https:\/\/doi.org\/10.1007\/s00432-022-04146-3.","DOI":"10.1007\/s00432-022-04146-3"},{"key":"506_CR34","volume-title":"Structural basis of ER-associated protein degradation mediated by the Hrd1 ubiquitin ligase complex","author":"X Wu","year":"2020","unstructured":"Wu X, Siggel M, Ovchinnikov S, Mi W, Svetlov V, Nudler E, et al. Structural basis of ER-associated protein degradation mediated by the Hrd1 ubiquitin ligase complex. Volume 368. New York, NY: Science; 2020. 6489."},{"key":"506_CR35","doi-asserted-by":"publisher","first-page":"12073","DOI":"10.1038\/ncomms12073","volume":"7","author":"Y Xu","year":"2016","unstructured":"Xu Y, Zhao F, Qiu Q, Chen K, Wei J, Kong Q, et al. The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity. Nat Commun. 2016;7:12073.","journal-title":"Nat Commun"},{"issue":"4","key":"506_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nsmb.2780","volume":"21","author":"CE Berndsen","year":"2014","unstructured":"Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol. 2014;21(4):301\u20137.","journal-title":"Nat Struct Mol Biol"},{"key":"506_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-biochem-060815-014922","volume":"86","author":"N Zheng","year":"2017","unstructured":"Zheng N, Shabek N. Ubiquitin ligases: structure, function, and Regulation. Annu Rev Biochem. 2017;86:129\u201357.","journal-title":"Annu Rev Biochem"},{"issue":"10","key":"506_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cac2.12192","volume":"41","author":"F Ji","year":"2021","unstructured":"Ji F, Zhou M, Sun Z, Jiang Z, Zhu H, Xie Z, et al. Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis. Cancer Commun (Lond). 2021;41(10):1007\u201323.","journal-title":"Cancer Commun (Lond)"},{"key":"506_CR39","doi-asserted-by":"crossref","unstructured":"Liu L, Yu L, Zeng C, Long H, Duan G, Yin G et al. E3 ubiquitin ligase HRD1 promotes lung tumorigenesis by promoting sirtuin 2 ubiquitination and degradation. Mol Cell Biol. 2020;40(7):e00257-19.","DOI":"10.1128\/MCB.00257-19"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-023-00506-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T04:08:03Z","timestamp":1686024483000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-023-00506-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s40364-023-00506-4","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethical Committee of Fujian Medical University Union Hospital and informed consent was obtained from each participant. All animal experiments were approved by the Committee on the Ethics of Animal Experiments of Fujian Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}